Investor Relations

alt
CAH 81.10 +0.00 +0% Volume: 1,397,108 03/23/17 16:00

Investor Relations

alt

Cardinal Health Reports Second-quarter Results for Fiscal Year 2017

Feb 7, 2017

- Revenue increased 5 percent to $33.1 billion
- GAAP1 operating earnings decreased 4 percent to $542 million, and non-GAAP operating earnings decreased 4 percent to $701 million
- GAAP diluted earnings per share increased 4 percent to $1.02, and non-GAAP diluted earnings per share increased 3 percent to $1.34
- Company updates fiscal year 2017 outlook

DUBLIN, Ohio, Feb. 7, 2017 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second-quarter fiscal year 2017 revenue of $33.1 billion, an increase of 5 percent. The company also reported a decline in GAAP operating earnings of 4 percent to $542 million and in non-GAAP operating earnings of 4 percent to $701 million. GAAP diluted earnings per share (EPS) increased 4 percent to $1.02, while non-GAAP diluted EPS increased 3 percent to $1.34.

"Our organization has shown great resilience in the first half of our fiscal 2017. While pricing in the generic pharmaceutical market was a significant headwind for our Pharmaceutical segment profit and our enterprise operating earnings, overall we are seeing greater growth in more lines of business than we've seen in some time," said George Barrett, chairman and CEO of Cardinal Health. "Of particular note, we saw strong growth in our Specialty Solutions group, and our Medical segment, where virtually every part of that business grew.

"As we enter the second half of the year, our organization continues to work with a clear sense of purpose – patient-centered and squarely focused on helping our partners improve the quality, safety and efficiency of the healthcare system."  

Q2 FY17 summary


Q2 FY17

Q2 FY16

Y/Y

Revenue

$33.1 billion

$31.4 billion

5%





Operating earnings

 $542 million

 $563 million

(4)%

Non-GAAP operating earnings

 $701 million

 $726 million

(4)%





Net earnings attributable to Cardinal Health, Inc.

 $324 million

 $326 million

 N.M.

Non-GAAP net earnings attributable to Cardinal Health, Inc.

 $427 million

 $430 million

(1)%





Diluted EPS attributable to Cardinal Health, Inc.

$1.02

$0.98

4%

Non-GAAP diluted EPS attributable to Cardinal Health, Inc.

$1.34

$1.30

3%

 

Diluted EPS for the quarter benefitted from a lower effective tax rate and fewer weighted average shares outstanding than the same quarter in the prior fiscal year.

Segment results

Pharmaceutical segment

Second-quarter revenue for the Pharmaceutical segment increased 5 percent to $29.7 billion due to growth from existing Pharmaceutical Distribution customers and strong performance from the Specialty business.

Segment profit for the quarter decreased 14 percent to $537 million. This decrease was driven by generic pharmaceutical pricing and, to a lesser extent, the previously announced loss of a large Pharmaceutical Distribution customer. This was partially offset by solid performance from Red Oak Sourcing.

 


Q2 FY17

Q2 FY16

Y/Y

Revenue

$29.7 billion

$28.3 billion

5%

Segment profit

$537 million

$627 million

(14)%

 

Medical segment

Second-quarter revenue for the Medical segment increased 8 percent to $3.4 billion, driven by contributions from net new and existing customers.

Segment profit increased 50 percent to $159 million due to the contribution from Cardinal Health Brand products, which includes Cordis. The increase reflects the $21 million unfavorable impact of the Cordis-related inventory fair value step-up in the second quarter of fiscal year 2016. Excluding this step-up, year-over-year Medical segment profit growth was 25 percent.

 


Q2 FY17

Q2 FY16

Y/Y

Revenue

$3.4 billion

$3.2 billion

8%

Segment profit

$159 million

$106 million

50%

 

Fiscal year 2017 outlook

As previously disclosed, the company does not provide GAAP EPS outlook, because it is unable to reliably forecast most of the items that are excluded from GAAP EPS to calculate non-GAAP EPS. These items could cause EPS to differ materially from non-GAAP EPS. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation.

Having completed more than half its fiscal year, the company is adjusting its fiscal year 2017 guidance range for non-GAAP diluted EPS from continuing operations to $5.35 to $5.50 from $5.40 to $5.60. This now reflects non-GAAP EPS growth of 2 to 5 percent for the fiscal year.

More details about this outlook can be found on the company's webcast and accompanying slides; see below for details.

Additional second-quarter and recent highlights

  • Renewed Department of Defense medical/surgical distribution prime vendor agreement

  • Signed several new strategic distribution agreements that will enable Cordis, Cardinal Health's interventional vascular business, to rapidly expand its product portfolio in select countries globally

  • Recognized Cincinnati Children's Hospital Medical Center as the recipient of the 2016 Award for Excellence in Medication Safety from the Cardinal Health Foundation and the American Society of Health-System Pharmacists Foundation

  • Chairman and CEO George Barrett named chairman of the Healthcare Leadership Council; Pharmaceutical Segment CEO Jon Giacomin named chairman of the Healthcare Distribution Alliance board

Webcast

Cardinal Health will host a webcast today at 8:30 a.m. Eastern to discuss second-quarter results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required. 

Presentation slides and a webcast replay will be available on the Cardinal Health website at ir.cardinalhealth.com until Feb. 6, 2018.

Upcoming webcasted investor events

  • Barclays Global Healthcare Conference on March 16 at 8:30 a.m. Eastern in Miami

About Cardinal Health

Cardinal Health Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically-proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Backed by nearly 100 years of experience, with more than 37,000 employees in nearly 60 countries, Cardinal Health ranks among the top 25 on the Fortune 500. For more information, visit cardinalhealth.com, follow @CardinalHealth on Twitter and connect on LinkedIn at linkedin.com/company/cardinal-health.

1 GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP.  See "Use of non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release, and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.

Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when the company posts news releases, SEC filings and certain other information on its website.

Cautions Concerning Forward-Looking Statements

This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results, trends or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include competitive pressures in Cardinal Health's various lines of business; the amount or rate of generic and branded pharmaceutical price appreciation or deflation and the timing of and benefit from generic pharmaceutical introductions; the ability to maintain the benefits from the generic sourcing venture with CVS Health; the ability to successfully integrate and realize the benefits from the acquisition of Cordis; the risk of non-renewal or a default under one or more key customer or supplier arrangements or changes to the terms of or level of purchases under those arrangements; uncertainties due to government health care reform including recent proposals to modify or repeal the Affordable Care Act; uncertainties with respect to U.S. tax and trade laws, including proposals relating to a "border adjustment tax" and new import tariffs; changes in the distribution patterns or reimbursement rates for health care products and services; the effects of any investigation or action by any regulatory authority; and changes in foreign currency rates and the cost of commodities such as oil-based resins, cotton, latex and diesel fuel. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management's views as of Feb. 7, 2017. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. 

 

 

Schedule 1

Cardinal Health, Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings (Unaudited)



Second Quarter



(in millions, except per common share amounts)

2017


2016


% Change

Revenue

$

33,150



$

31,445



5%

Cost of products sold

31,548



29,836



6%

Gross margin

1,602



1,609



—%







Operating expenses:






Distribution, selling, general and administrative expenses

910



922



(1)%

Restructuring and employee severance

7



2



N.M.

Amortization and other acquisition-related costs

115



114



N.M.

Impairments and loss on disposal of assets, net

9



17



N.M.

Litigation (recoveries)/charges, net

19



(9)



N.M.

Operating earnings

542



563



(4)%







Other (income)/expense, net

7



(2)



N.M.

Interest expense, net

44



45



(2)%

Earnings before income taxes

491



520



(6)%







Provision for income taxes

167



194



(14)%

Net earnings

324



326



—%







Less: Net earnings attributable to noncontrolling interests





N.M.

Net earnings attributable to Cardinal Health, Inc.

$

324



$

326



—%







Earnings per common share attributable to Cardinal Health, Inc.:






Basic

$

1.02



$

0.99



3%

Diluted

1.02



0.98



4%







Weighted-average number of common shares outstanding:






Basic

318



329




Diluted

319



332




 

 

 

Schedule 2


Cardinal Health, Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings (Unaudited)





Year-to-Date




(in millions, except per common share amounts)

2017


2016


% Change


Revenue

$

65,189



$

59,499



10%


Cost of products sold

61,997



56,311



10%


Gross margin

3,192



3,188



—%









Operating expenses:







Distribution, selling, general and administrative expenses

1,831



1,764



4%


Restructuring and employee severance

16



14



N.M.


Amortization and other acquisition-related costs

237



219



N.M.


Impairments and loss on disposal of assets, net

12



17



N.M.


Litigation (recoveries)/charges, net

20



(9)



N.M.


Operating earnings

1,076



1,183



(9)%









Other expense, net

3



6



N.M.


Interest expense, net

88



90



(2)%


Earnings before income taxes

985



1,087



(9)%









Provision for income taxes

351



377



(7)%


Net earnings

634



710



(11)%









Less: Net earnings attributable to noncontrolling interest

(1)



(1)



N.M.


Net earnings attributable to Cardinal Health, Inc.

$

633



$

709



(11)%









Earnings per common share attributable to Cardinal Health, Inc.:







Basic

$

1.99



$

2.16



(8)%


Diluted

1.97



2.14



(8)%









Weighted-average number of common shares outstanding:







Basic

319



329





Diluted

321



332





 

 

Schedule 3

Cardinal Health, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Unaudited)


(in millions)

December 31,
 2016


June 30,
 2016

Assets




Current assets:




Cash and equivalents

$

1,881



$

2,356


Trade receivables, net

7,533



7,405


Inventories, net

11,915



10,615


Prepaid expenses and other

1,824



1,580


Total current assets

23,153



21,956






Property and equipment, net

1,856



1,796


Goodwill and other intangibles, net

9,276



9,426


Other assets

736



944


Total assets

$

35,021



$

34,122






Liabilities, Redeemable Noncontrolling Interests and Shareholders' Equity




Current liabilities:




Accounts payable

$

18,857



$

17,306


Current portion of long-term obligations and other short-term borrowings

603



587


Other accrued liabilities

1,554



1,808


Total current liabilities

21,014



19,701






Long-term obligations, less current portion

4,859



4,952


Deferred income taxes and other liabilities

2,692



2,781






Redeemable noncontrolling interests

115



117






Total Cardinal Health, Inc. shareholders' equity

6,323



6,554


Noncontrolling interests

18



17


Total shareholders' equity

6,341



6,571


Total liabilities, redeemable noncontrolling interests and shareholders' equity

$

35,021



$

34,122


 

 

Schedule 4

Cardinal Health, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Unaudited)



Second Quarter


Year-to-Date

(in millions)

2017


2016


2017


2016

Cash flows from operating activities:








Net earnings

$

324



$

326



$

634



$

710










Adjustments to reconcile net earnings to net cash from operating activities:








Depreciation and amortization

166



169



339



306


Impairments and loss on sale of other investments

3





3




Impairments and loss on disposal of assets, net

9



17



12



17


Share-based compensation

24



26



47



56


Provision for bad debts

22



18



29



35


Change in fair value of contingent consideration obligation



(13)





(14)


Change in operating assets and liabilities, net of effects from acquisitions:








Decrease/(increase) in trade receivables

160



(45)



(146)



(393)


Increase in inventories

(996)



(1,070)



(1,294)



(1,565)


Increase in accounts payable

1,284



2,006



1,563



2,431


Other accrued liabilities and operating items, net

(442)



29



(529)



(172)


Net cash provided by operating activities

554



1,463



658



1,411










Cash flows from investing activities:








Acquisition of subsidiaries, net of cash acquired

(2)



(1,885)



(11)



(3,284)


Additions to property and equipment

(113)



(92)



(213)



(175)


Purchase of available-for-sale securities and other investments

(73)



(62)



(125)



(88)


Proceeds from sale of available-for-sale securities and other investments

38



32



72



57


Proceeds from maturities of available-for-sale securities

22



14



39



19


Proceeds from divestitures and disposal of property and equipment and held for sale assets

1





1




Net cash used in investing activities

(127)



(1,993)



(237)



(3,471)










Cash flows from financing activities:








Payment of contingent consideration obligation







(23)


Net change in short-term borrowings

8



3



33



39


Net purchase of noncontrolling interests

(2)





(12)




Reduction of long-term obligations

(59)





(60)



(4)


Proceeds from interest rate swap terminations





14




Net tax proceeds/(withholdings) from share-based compensation

9



14





(7)


Tax proceeds from share-based compensation

2



1



32



32


Dividends on common shares

(144)



(128)



(293)



(259)


Purchase of treasury shares

(350)





(600)




Net cash used in financing activities

(536)



(110)



(886)



(222)










Effect of exchange rates changes on cash and equivalents

(11)



(10)



(10)



(10)










Net decrease in cash and equivalents

(120)



(650)



(475)



(2,292)


Cash and equivalents at beginning of period

2,001



2,974



2,356



4,616


Cash and equivalents at end of period

$

1,881



$

2,324



$

1,881



$

2,324


 

 

Schedule 5

Cardinal Health, Inc. and Subsidiaries

Segment Business Analysis



Second Quarter



Second Quarter

(in millions)

2017


2016


(in millions)

2017


2016

Pharmaceutical





Medical













Revenue





Revenue




Amount

$

29,743



$

28,287



Amount

$

3,410



$

3,162


Growth rate

5%



25%



Growth rate

8%



9%











Segment profit





Segment profit




Amount

$

537



$

627



Amount

$

159



$

106


Growth rate

(14)%



16%



Growth rate1

50%



(8)%


Segment profit margin

1.81%



2.22%



Segment profit margin

4.68%



3.36%




1.

Segment profit for three months ended December 31, 2015 includes a $21 million unfavorable impact of Cordis-related inventory fair value step-up. Excluding
this step-up, year-over-year Medical segment profit growth was 25 percent and 10 percent for the three months ended December 31, 2016 and 2015,
respectively.

 

Refer to definitions for an explanation of calculations.

Total consolidated revenue for the three months ended December 31, 2016 was $33,150 million, which included total segment revenue of $33,153 million and Corporate revenue of $(3) million. Total consolidated revenue for the three months ended December 31, 2015 was $31,445 million, which included total segment revenue of $31,449 million and Corporate revenue of $(4) million. Corporate revenue consists primarily of elimination of inter-segment revenue and other revenue not allocated to the segments.

Total consolidated operating earnings for the three months ended December 31, 2016 were $542 million, which included total segment profit of $696 million and Corporate costs of $(154) million. Total consolidated operating earnings for the three months ended December 31, 2015 were $563 million, which included total segment profit of $733 million and Corporate costs of $(170) million. Corporate includes, among other things, LIFO charges/(credits), restructuring and employee severance, amortization and other acquisition-related costs, impairments and (gain)/loss on disposal of assets, litigation (recoveries)/charges, net and certain investment spending that are not allocated to the segments.

 

 

Schedule 6

Cardinal Health, Inc. and Subsidiaries

Segment Business Analysis



Year-to-Date



Year-to-Date

(in millions)

2017


2016


(in millions)

2017


2016

Pharmaceutical





Medical













Revenue





Revenue




Amount

$

58,505



$

53,427



Amount

$

6,690



$

6,081


Growth rate

10%



22%



Growth rate

10%



5%











Segment profit





Segment profit




Amount

$

1,071



$

1,285



Amount

$

286



$

207


Growth rate

(17)%



29%



Growth rate1

39%



(10)%


Segment profit margin

1.83%



2.41%



Segment profit margin

4.28%



3.40%




1.

Segment profit for the six months ended December 31, 2015 includes the $21 million unfavorable impact of the Cordis-related inventory step-up. Excluding this
step-up, year-over-year Medical segment profit growth was 25 percent and flat for the six months ended December 31, 2016 and 2015, respectively.

 

Refer to definitions for an explanation of calculations.

Total consolidated revenue for the six months ended December 31, 2016 was $65,189 million, which included total segment revenue of $65,195 million and Corporate revenue of $(6) million. Total consolidated revenue for the six months ended December 31, 2015 was $59,499 million, which included total segment revenue of $59,508 million and Corporate revenue of $(9) million.  Corporate revenue consists primarily of elimination of inter-segment revenue and other revenue not allocated to the segments.

Total consolidated operating earnings for the six months ended December 31, 2016 were $1,076 million, which included total segment profit of $1,357 million and Corporate costs of $(281) million. Total consolidated operating earnings for the six months ended December 31, 2015 were $1,183 million, which included total segment profit of $1,492 million and Corporate costs of $(309) million. Corporate includes, among other things, LIFO charges/(credits), restructuring and employee severance, amortization and other acquisition-related costs, impairments and (gain)/loss on disposal of assets, litigation (recoveries)/charges, net and certain investment spending that are not allocated to the segments.

 

 

Schedule 7


Cardinal Health, Inc. and Subsidiaries

GAAP / Non-GAAP Reconciliation1









Gross


Operating

Earnings

Provision








Margin


Earnings

Before

for


Net


Diluted



Gross

Growth

Operating

Growth

Income

Income

Net

Earnings2

Diluted

EPS2


(in millions, except per common share amounts)

Margin

Rate

Earnings

Rate

Taxes

Taxes

Earnings2

Growth Rate

EPS2,3,4

Growth Rate


Second Quarter 2017


GAAP

$

1,602


—%

$

542


(4)%

$

491


$

167


$

324


—%

$

1.02


4%


LIFO charges/(credits)

9



9



9


4


5



0.02




Restructuring and employee severance



7



7


2


5



0.01




Amortization and other acquisition-related costs



115



115


39


76



0.24




Impairments and (gain)/loss on disposal of assets



9



9


3


6



0.02




Litigation (recoveries)/charges, net



19



19


7


12



0.04




Non-GAAP

$

1,611


(2)%

$

701


(4)%

$

650


$

222


$

427


(1)%

$

1.34


3%















Second Quarter 2016


GAAP

$

1,609


11%

$

563


3%

$

520


$

194


$

326


13%

$

0.98


14%


LIFO charges/(credits)

39



39



39


15


24



0.07




Restructuring and employee severance



2



2


1


1






Amortization and other acquisition-related costs



114



114


41


73



0.22




Impairments and (gain)/loss on disposal of assets



17



17


7


10



0.03




Litigation (recoveries)/charges, net



(9)



(9)


(5)


(4)



(0.01)




Non-GAAP

$

1,648


13%

$

726


14%

$

683


$

253


$

430


7%

$

1.30


8%




























Gross


Operating

Earnings

Provision








Margin


Earnings

Before

for


Net


Diluted



Gross

Growth

Operating

Growth

Income

Income

Net

Earnings2

Diluted

EPS2


(in millions, except per common share amounts)

Margin

Rate

Earnings

Rate

Taxes

Taxes

Earnings2

Growth Rate

EPS2

Growth Rate


Year-to-Date 2017


GAAP

$

3,192


—%

$

1,076


(9)%

$

985


$

351


$

633


(11)%

$

1.97


(8)%


LIFO charges/(credits)

9



9



9


4


5



0.02




Restructuring and employee severance



16



16


6


10



0.03




Amortization and other acquisition-related costs



237



237


79


158



0.49




Impairments and (gain)/loss on disposal of assets



12



12


4


8



0.02




Litigation (recoveries)/charges, net



20



20


8


12



0.04




Non-GAAP

$

3,201


(1)%

$

1,370


(6)%

$

1,279


$

452


$

826


(7)%

$

2.57


(4)%















Year-to-Date 2016


GAAP

$

3,188


14%

$

1,183


17%

$

1,087


$

377


$

709


28%

$

2.14


30%


LIFO charges/(credits)

39



39



39


15


24



0.07




Restructuring and employee severance



14



14


5


9



0.02




Amortization and other acquisition-related costs



219



219


78


141



0.42




Impairments and (gain)/loss on disposal of assets



17



17


7


10



0.03




Litigation (recoveries)/charges, net



(9)



(9)


(5)


(4)



(0.01)




Non-GAAP

$

3,227


15%

$

1,463


22%

$

1,368


$

479


$

889


20%

$

2.68


22%


 

1For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.

2attributable to Cardinal Health, Inc.

3GAAP diluted EPS for the three months ended December 31, 2016 compared to the prior year period was favorably impacted by $0.09, which includes $0.05 due to change in the effective tax rate and $0.04 due to the change in weighted average shares outstanding. The change in GAAP diluted EPS due to the effective tax rate is calculated as ((GAAP Earnings before Income Taxes for the current period times (one minus the current period GAAP Effective Tax Rate)) minus (GAAP Earnings before Income Taxes for the current period times (one minus the prior period GAAP Effective Tax Rate))) divided by the current period weighted average shares outstanding. The change in GAAP diluted EPS due to the weighted average shares outstanding is calculated as (GAAP Net Earnings for the current period divided by the current period weighted average shares outstanding) minus (GAAP Net Earnings for the current period divided by the prior period weighted average shares outstanding).

4Non-GAAP diluted EPS for the three months ended December 31, 2016 compared to the prior year period was favorably impacted by $0.11, which includes $0.06 due to change in the effective tax rate and $0.05 due to the change in weighted average shares outstanding. The change in Non-GAAP diluted EPS due to the effective tax rate is calculated as ((Non-GAAP Earnings before Income Taxes for the current period times (one minus the current period Non-GAAP Effective Tax Rate)) minus (Non-GAAP Earnings before Income Tax for the current period times (one minus the prior period Non-GAAP Effective Tax Rate))) divided by the current period weighted average shares outstanding. The change in Non-GAAP diluted EPS due to the weighted average shares outstanding is calculated as (Non-GAAP Net Earnings for the current period divided by the current period weighted average shares outstanding) minus (Non-GAAP Net Earnings for the current period divided by the prior period weighted average shares outstanding).

The sum of the components may not equal the total due to rounding.

We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

There were no losses on extinguishment of debt during the periods presented.

Schedule 8

Cardinal Health, Inc. and Subsidiaries

GAAP / Non-GAAP Reconciliation



Second Quarter

(in millions)

2017


2016

GAAP effective tax rate

34.0

%


37.3

%





Non-GAAP effective tax rate




Earnings before income taxes

$

491



$

520


LIFO charges

9



39


Restructuring and employee severance

7



2


Amortization and other acquisition-related costs

115



114


Impairments and loss on disposal of assets

9



17


Litigation (recoveries)/charges, net

19



(9)


Adjusted earnings before income taxes

$

650



$

683






Provision for income taxes

$

167



$

194


LIFO charges tax benefit

4



15


Restructuring and employee severance tax benefit

2



1


Amortization and other acquisition-related costs tax benefit

39



41


Impairments and loss on disposal of assets tax benefit

3



7


Litigation (recoveries)/charges, net tax benefit/(expense)

7



(5)


Adjusted provision for income taxes

$

222



$

253






Non-GAAP effective tax rate

34.2

%


37.1

%

The sum of the components may not equal the total due to rounding.

We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

 

Cardinal Health, Inc. and Subsidiaries

Use of Non-GAAP Measures
This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP").

In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, evaluate the balance sheet, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.

Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this earnings release for its own and for investors' assessment of the business for the reasons identified below:

  • LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges from non-GAAP metrics allows for a better comparison of our current financial results to our historical financial results and to our peer group companies' financial results.
  • Restructuring and employee severance costs are excluded because they relate to programs in which we fundamentally change our operations and because they are not part of the ongoing operations of our underlying business, which includes normal levels of reinvestment in the business.
  • Amortization and other acquisition-related costs are excluded primarily for consistency with the presentation of the financial results of our peer group companies. Additionally, these non-cash amounts are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion allows for better comparison of historical, current and forecasted financial results. We exclude other acquisition-related costs because they are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity's initial balance sheet as part of the purchase price allocation. They are also significantly impacted by the timing and size of acquisitions.
  • Impairments and gains or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and their exclusion results in a metric that more meaningfully reflects the sustainability of our operating performance.
  • Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
  • Loss on extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt financing transactions.

The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.

Forward Looking Non-GAAP Measures
In this earnings release, the Company presents its outlook for fiscal 2017 non-GAAP EPS.  The Company does not provide EPS outlook, which is the most directly comparable GAAP measure to non-GAAP EPS, because changes in the items that the Company excludes from EPS to calculate non-GAAP EPS, described above, can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company's routine operating activities. Additionally, due to their unpredictability, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on an EPS outlook.

The timing and amount of any of the excluded items could significantly impact the Company's fiscal 2017 EPS. Over the past five fiscal years, the excluded items have lowered the Company's EPS from $0.14 to $2.76, which includes a goodwill impairment charge of $2.32 per share related to our Nuclear Pharmacy Services division that we recognized in fiscal 2013.

Definitions

Growth rate calculation: Growth rates in this earnings release are determined by dividing the difference between current period results and prior period results by prior period results.

Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) restructuring and employee severance, (3) amortization and other acquisition-related costs, (4) impairments and (gain)/loss on disposal of assets and (5) litigation (recoveries)/charges, net.

Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) restructuring and employee severance, (3) amortization and other acquisition-related costs, (4) impairments and (gain)/loss on disposal of assets, (5) litigation (recoveries)/charges, net and (6) loss on extinguishment of debt.

Non-GAAP effective tax rate: (provision for income taxes adjusted for (1) LIFO charges/(credits), (2) restructuring and employee severance, (3) amortization and other acquisition-related costs, (4) impairments and (gain)/loss on disposal of assets, (5)  litigation (recoveries)/charges, net, and (6) loss on extinguishment of debt) divided by (earnings before income taxes adjusted for the same six items).

Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) restructuring and employee severance, (3) amortization and other acquisition-related costs, (4) impairments and (gain)/loss on disposal of assets, (5) litigation (recoveries)/charges, net and (6) loss on extinguishment of debt, each net of tax.

Non-GAAP diluted EPS attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.

 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cardinal-health-reports-second-quarter-results-for-fiscal-year-2017-300403281.html

SOURCE Cardinal Health

Media: Ellen Barry, (614) 553-3858, ellen.barry@cardinalhealth.com; Investors: Lisa Capodici, (614) 757-5035, lisa.capodici@cardinalhealth.com